Axumin® (fluciclovine F 18) injection was specifically developed to enhance PET/CT imaging

Axumin is indicated for Positron Emission Tomography—Computed Tomography (PET/CT) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.1

Axumin contains fluciclovine, a fluorine 18 (F 18) labeled synthetic amino acid analog with a 109.7 minute half-life1

Fluciclovine F 18 is taken up to a greater extent in prostate cancer cells than in surrounding normal tissues, enabling the visualization of recurrent prostate cancer.1,2

It is transported into cells by amino acid transporters, such as ASCT2 and LAT1, which are upregulated in prostate cancer.1

Mechanism of action for Axumin

Axumin mechanism of action: Increased uptake of fluciclovine into prostate cancer cells by upregulated amino acid transporters, such as ASCT2 and LAT1.1-4


  1. Axumin [package insert]. Oxford, UK: Blue Earth Diagnostics Ltd; 2016.
  2. Schuster DM, Savir-Baruch B, Nieh PT, et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and111In-capromab pendetide SPECT/CT. Radiology. 2011:259(3):852-861.
  3. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in Crime? Sem Cancer Biol. 2005;15:254-266.
  4. Okudaira H, Oka S, Ono M, et al. Accumulation of Trans-1-Amino-3-[18F]Fluorocyclobutanecarboxylic Acid in Prostate Cancer due to Androgen-Induced Expression of Amino Acid Transporters. Mol Imaging Biol. 2014;16:756-764.